Axsome Therapeutics, Inc.
AXSM
Rang in Aktien
#2344
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aktienkurs
$159.89
Marktkapitalisierung
$8.37B
Veränderung (1 Tag)
2.62%
Veränderung (1 Jahr)
21.49%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategorie
Healthcare
Gewinn für Axsome Therapeutics, Inc. (AXSM)
Gewinn im Jun 2026 TTM: $-191.09M
Laut den aktuellen Finanzberichten von Axsome Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-191.09M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-238.28M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-187.13M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Axsome Therapeutics, Inc. von 2013 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-191.09M | -33.45% |
| 2024 | $-287.13M | 20.50% |
| 2023 | $-238.28M | 27.33% |
| 2022 | $-187.13M | 43.50% |
| 2021 | $-130.40M | 26.73% |
| 2020 | $-102.90M | 50.56% |
| 2019 | $-68.35M | 120.71% |
| 2018 | $-30.97M | 6.99% |
| 2017 | $-28.94M | 6.40% |
| 2016 | $-27.20M | 157.60% |
| 2015 | $-10.56M | 75.98% |
| 2014 | $-6.00M | 176.95% |
| 2013 | $-2.17M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -2,860.48% |
US
|
|
| $-3.09B | 1,515.50% |
US
|
|
| $-4.02B | 2,001.77% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,120.82% |
NL
|
